Simcha Therapeutics
Company Details
Status: Private
Employees: 1-10
Location:
New Haven, Connecticut, United States
Type:
sample
Technology:
sample
About: Simcha Therapeutics is a clinical-stage immunobiology company pioneering the development of first-in-class engineered cytokine therapeutics with transformational promise for patients. The company is built on a foundation of scientific rigor to overcome biological challenges in clinically translatable pathways, exemplified by the first decoy-resistant interleukin-18 (IL-18). By unlocking the potential of IL-18, Simcha is developing its lead program (ST-067) as monotherapy and in combination with potentially several other anticancer agents. ST-067 is currently being studied in a Phase 1/2 clinical trial, in patients with solid tumors and who have progressed on other immunotherapeutic agents. Beyond IL-18, the company’s underlying approach to immune-biology and cytokine engineering has broader potential to support disease-modifying therapeutic options for a range of significant diseases.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Simcha Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.